News

Click here for Webcast Net Revenues Total $4.9 Billion Non-GAAP Diluted EPS of $1.12; GAAP Diluted EPS of $0.74 Cash Flow from Operations of $1.1 Billion JERUSALEM--(BUSINESS WIRE)--May. 2, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended March 31, 2013. “During the quarter, we were pleased by the overall performance of our specialty products and results of our OTC joint venture. Our generic operations, which are a core component of our business, performed in line with our expectations and were particularly strong in Western and East Read More »

JERUSALEM--(BUSINESS WIRE)--Jan. 22, 2013-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its fourth quarter and full year 2012 financial results on Thursday, February 7, 2013 at 7:00 a.m. EST. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. EST to discuss its fourth quarter and full year 2012 results and overall business environment. A Question & Answer session will follow this discussion. In order to participate, please dial the following num Read More »

Click here for Webcast Net Revenues Total $5.0 Billion, up 14% Non-GAAP EPS of $1.28, up 2% JERUSALEM--(BUSINESS WIRE)--Nov. 1, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended September 30, 2012. Highlights: Net revenues of $5.0 billion, compared to $4.3 billion in the third quarter of 2011, an increase of 14%. Net revenues organic growth of 1.3% compared to the third quarter of 2011, and 6% organic growth excluding the effect of generic competition on Provigil®. GAAP net income (loss) and GAAP diluted EPS of $(79) million and Read More »

Click here for Webcast Net Revenues Total $5.0 Billion, up 19% GAAP EPS of $0.99, up 55%; Non-GAAP EPS of $1.28, up 16% JERUSALEM--(BUSINESS WIRE)--Aug. 2, 2012-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today reported results for the quarter ended June 30, 2012. Highlights: Net revenues of $5.0 billion, compared to $4.2 billion in the second quarter of 2011, an increase of 19%. Net revenues organic growth of 3% compared to the second quarter of 2011, and 7% excluding the effect of generic competition on Provigil®. GAAP net income and GAAP diluted EPS of $863 million and Read More »

Fourth Quarter Net Revenues Total $5.7 Billion, up 28%, with Non-GAAP EPS of $1.59, up 27% Full Year 2011 Net Revenues Total $18.3 Billion, up 14%, with Non-GAAP EPS of $4.97, up 9% 25% Increase in Quarterly Dividend to NIS 1.00 Per Share JERUSALEM--(BUSINESS WIRE)--Feb. 15, 2012-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today reported results for the quarter and year ended December 31, 2011. Q4 2011 Highlights: Net revenues of $5.7 billion, compared to $4.4 billion i Read More »

JERUSALEM, Nov 02, 2011 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today reported results for the quarter ended September 30, 2011. Third Quarter Highlights:1 Net sales of $4.34 billion, compared to $4.25 billion in the third quarter of 2010, an increase of 2% and $4.21 billion in the second quarter of 2011, an increase of 3%. Non-GAAP net income and non-GAAP EPS of $1,111 million and $1.25, compared to $1,182 million and $1.30, respectively, in the third quarter of 2010, and $984 million and $1.10, respectively, in the second quarter of 2011. Quarterly GAAP n Read More »

Financial Tables -- 11% Growth in Sales; Record Cash Flow -- JERUSALEM, Jul 27, 2011 (BUSINESS WIRE) -- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today reported results for the quarter ended June 30, 2011. Second Quarter Highlights: Quarterly net sales of $4.2 billion, an increase of 11%.1 Quarterly non-GAAP net income and non-GAAP EPS of $984 million and $1.10, compared to $981 million and $1.08, respectively. Quarterly GAAP net income was $576 million, compared to $797 million; GAAP EPS totaled $0.64, compared to $0.88. Strong sales growth in Europe of 82% (60% in Read More »